Financials

News Ideas Discussions Technicals Seasonals

KAN fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Kancera AB engages in the research, development, and sale of drug candidates to pharmaceutical companies. It focuses on Fractalkine program which develops a candidate drugs for treatment of severe inflammatory diseases and cancer. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

KAN has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company